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We report on the in vitro effects of the bumped kinase inhibitor 1294 (BKI-1294) in cultures of virulentNeospora caninum iso-
lates Nc-Liverpool (Nc-Liv) and Nc-Spain7 and in two strains of Toxoplasma gondii (RH andME49), all grown in human fore-
skin fibroblasts. In these parasites, BKI-1294 acted with 50% inhibitory concentrations (IC50s) ranging from 20 nM (T. gondii
RH) to 360 nM (N. caninumNc-Liv), and exposure of intracellular stages to 1294 led to the nondisjunction of newly formed
tachyzoites, resulting in the formation of multinucleated complexes similar to complexes previously observed in BKI-1294-
treated N. caninum beta-galactosidase-expressing parasites. However, such complexes were not seen in a transgenic T. gondii
strain that expressed CDPK1 harboring a mutation (G to M) in the gatekeeper residue. In T. gondiiME49 andN. caninumNc-
Liv, exposure of cultures to BKI-1294 resulted in the elevated expression of mRNA coding for the bradyzoite marker BAG1. Un-
like in bradyzoites, SAG1 expression was not repressed. Immunofluorescence also showed that these multinucleated complexes
expressed SAG1 and BAG1 and the monoclonal antibody CC2, which binds to a yet unidentified bradyzoite antigen, also exhib-
ited increased labeling. In a pregnant mouse model, BKI-1294 efficiently inhibited vertical transmission in BALB/c mice experi-
mentally infected with one of the two virulent isolates Nc-Liv or Nc-Spain7, demonstrating proof of concept that this compound
protected offspring from vertical transmission and disease. The observed deregulated antigen expression effect may enhance the
immune response during BKI-1294 therapy and will be the subject of future studies.
Neospora caninum is a cyst-forming apicomplexan parasite thatis closely related to Toxoplasma gondii but exhibits distinct
differences in transmission patterns, virulence, host specificity,
immunogenetic aspects, and the pathology it induces. T. gondii
causes toxoplasmosis in humans and many domestic and wildlife
animals, with great economic impact especially in sheep but also
in many other animal species (1). Human toxoplasmosis causes
serious pathology in immune-suppressed individuals. In addi-
tion, if a seronegative mother acquires primary infection during
pregnancy, human toxoplasmosis can lead to abortion, micro-
cephalus and hydrocephalus, and other fetal abnormalities caus-
ing intellectual disability (2). N. caninum is a veterinary health
problem and represents one of the most important infectious
causes of bovine abortion, stillbirth, and the birth of weak calves,
with an economic impact of over $1.3 billion (3–5). In addition,
N. caninum causes neuromuscular disease in dogs, and neosporo-
sis has also been detected in a wide range of other species of live-
stock and wild animals worldwide.
Despite their differences, an important common feature of
these parasites is their ability to invade and replicate within a wide
range of cell types and tissues, where they reside in an intracellular
parasitophorous vacuole, surrounded by a parasitophorous vacu-
ole membrane. Repeated cycles of invasion, proliferation, and
egress of the disease-causing tachyzoites are responsible for induc-
ing the pathological effects that occur during the acute stage of
infection. In turn, chronic infection is characterized by the forma-
tion of intracellular tissue cysts in brain and muscular tissues that
harbor slowly proliferating bradyzoites. Calcium-dependent pro-
tein kinases (CDPKs), encoded by apicoplast-associated genes
and, thus, only found in apicomplexan parasites and plants, rep-
resent excellent drug targets in several apicomplexans such as
Plasmodium falciparum (6),Cryptosporidium parvum (7, 8) where
novel drug targets are of crucial interest (9), N. caninum (10),
Eimeria tenella, and Babesia bovis (11). Excellent correlations be-
tween cell activity and CDPK1 inhibition were achieved by com-
pounds from a focused bumped kinase inhibitor (BKI) library. In
many apicomplexan CDPK1 enzymes, including T. gondii andN.
caninum, the ATP binding pocket is characterized by a glycine as
the smallest possible gatekeeper residue. The T. gondii strain
CDPK1_G128M, overexpressing a CDPK1 version with a muta-
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tion (G to M) in the ATP binding pocket, was found to be much
less sensitive to BKIs (12).
We have previously demonstrated the outstanding efficacy of
BKI-1294 against transgenic beta-galactosidase-expressing N.
caninum tachyzoites (Nc-betaGal) in vitro and in a nonpregnant
mouse model for cerebral infection (10). In addition, we have
shown that for the BKI-1294-inhibited egress of Nc-betaGal
tachyzoites in vitro, once located intracellularly, parasites under-
went nuclear division but cytokinesis was not achieved, which
resulted in the formation of large multinucleated complexes that
remained trapped within the host cell and eventually died (10).
However, it is currently unclear whether this incomplete cytoki-
nesis was caused specifically by CDPK1 inhibition or whether an-
other target may be potentially involved (13).
In this study, we compared in vitro effects of BKI-1294 in
tachyzoite cultures of the virulent N. caninum isolates Nc-Liver-
pool (Nc-Liv) and Nc-Spain7 and in two strains of T. gondii (RH
and ME49). In order to investigate the direct role of CDPKI, we
have included the T. gondii strain overexpressing the gatekeeper
mutation G128M and a control strain overexpressing the wild-
type CDPKI in our study. We show that BKI-1294 does not only
interfere in tachyzoite invasion but also causes incomplete cytoki-
nesis resulting in the formation of multinucleated complexes in
the two species but not in the transgenicT. gondii strain expressing
CDPK1 harboring a mutation (G toM) in the gatekeeper residue.
Moreover, we present data on antigen expression in these multi-
nucleate complexes. We also show that BKI-1294 inhibits vertical
transmission of Nc-Liv and Nc-Spain7 in a pregnant mouse
model forN. caninum infection. Our data provide a proof of con-
cept for the treatment ofN. caninum infection and the protection
of offspring by BKI-1294 and related compounds.
MATERIALS AND METHODS
Tissue culture media, biochemicals, and drugs. If not stated otherwise,
all tissue culture media were purchased from Gibco-BRL (Zürich, Swit-
zerland), and biochemical reagents were from Sigma (St. Louis,MO). Kits
for molecular biology were purchased from Qiagen (Hilden, Germany).
BKI-1294 was obtained from the Center for Emerging and Reemerging
Infectious Diseases (CERID), Division of Allergy and Infectious Diseases,
Department of Medicine, University of Washington (Seattle, WA, USA).
For in vitro studies, the compoundwas stored as a 20mMstock solution in
dimethyl sulfoxide (DMSO) at20°C; for application in mice, BKI-1294
powder was suspended either in 0.5% carboxymethyl cellulose (CMC) in
water or in corn oil, and the suspensions were applied by gavage.
Host cell cultivation and parasite cultures. Human foreskin fibro-
blasts (HFF) were maintained in Dulbecco’s modified Eagle medium
(DMEM), and Vero cells were cultured in RPMI 1640medium, each with
phenol red supplemented with 10% heat-inactivated and sterile filtered
fetal calf serum (FCS), 50 U of penicillin/ml, and 50 g streptomycin/ml
(culture medium). Cultures were maintained at 37°C and 5% CO2 in
tissue culture flasks (Sarstedt, Sevelen, Switzerland) and were passaged at
least once a week.
Tachyzoites of N. caninum isolates Nc-Liverpool (Nc-Liv) and
Nc-Spain7, T. gondii strains ME49 and RH, the T. gondii strain
CDPK1_G128M overexpressing a CDPK1 with the gatekeeper mutation
G128M, and an isogenic strain, T. gondii CDPK_wt, expressing the wild-
typeCDPK1 (12)were allmaintained by serial passages in eitherVero cells
or HFF in their respective media (14, 15). Tachyzoites were harvested by
removing infected cell layers with a rubber cell scraper followed by re-
peated passages through a 25-gauge needle at 4°C. For in vitro studies,
tachyzoites were separated from cell debris on a Sephadex G-25 column
(16). For in vivo experiments, purification over Sephadex G-25 columns
was omitted.
Determination of 50% inhibitory concentrations. HFF were grown
in 6-well plates for 24 h until a confluent monolayer was formed. Just
prior to infection, the BKI-1294 was added at a final concentration of 2.5
M for initial experiments and ranged between 0.5 nM and 2.5 M for
50% effective concentration (EC50) determinations (the effective concen-
tration to reduce proliferation by 50%). Controls received the corre-
sponding amounts of DMSO.HFFwere then infectedwith 5 104 freshly
purified tachyzoites ofN. caninumNc-Liv, Nc-Spain7, T. gondiiME49, T.
gondii CDPK1_G128M, or T. gondii CDPK1_wt in 5 ml medium. After 4
days, cells were collected with a cell scraper, centrifuged, washed once
more in phosphate-buffered saline (PBS), and the pellet was stored at
20°Cprior to quantification of parasite proliferation.DNA purification
was performed employing the DNeasy blood and tissue kit (Qiagen,
Basel, Switzerland) according to the standard protocol suitable for
animal cells. N. caninum parasite load was determined by real-time
PCR as previously described (15). Proliferation of T. gondii ME49, T.
gondii CDPK1_G128M, and T. gondii CDPK1_wt tachyzoites was quan-
tified as described previously (17). The parasite counts were calculated by
interpolation from a standard curve with DNA equivalents from 1,000,
100, and 10 culture-derived tachyzoites included in each run.
Transmission electron microscopy. HFF were grown to confluence
in T25 flasks and were infected with T. gondii ME49, T. gondii RH, T.
gondii CDPK1_G128M, T. gondii CDPK1_wt, or N. caninum Nc-Liv
tachyzoites. After 24 h, cultures were supplemented with 2.5 M BKI-
1294; infected cultures treated with DMSO served as controls. After 2, 4,
and 6 days of treatment, the monolayers were washed with 100 mM so-
dium cacodylate buffer (pH 7.3) and fixedwith cacodylate buffer contain-
ing 2.5% glutaraldehyde for 10 min (18). Cells were collected using a
rubber cell scraper and centrifuged for 10 min at 1,200 rpm and room
temperature. The supernatant was removed, and infected cells were fixed
further in glutaraldehyde-cacodylate at 4°C overnight. Postfixation in 2%
OsO4, dehydration, embedding in Epon 820 epoxy resin, and cutting of
ultrathin sections was done as previously described (18, 19). Specimens
were viewed on a Phillips 400 transmission electron microscope (TEM)
operating at 80 kV.
Measurement of BAG1 and SAG1 RNA expression during drug
treatment by reverse transcriptase real-time PCR. Confluent HFF
monolayers grown in 6-well plates were infected with 2.5 104 N. cani-
num or T. gondii tachyzoites. Treatments with 5 MBKI-1294 or DMSO
alonewere initiated 2 days postinfection (p.i.). After different time points,
medium supernatant was removed, the monolayers were washed once in
PBS, and the adherent cells were carefully removed with a rubber cell
scraper. The suspensionwas transferred to a tube, and after centrifugation
at 600 g for 10 min at 4°C, the supernatant was removed and the pellet
resuspended in 350l RLT buffer of the RNeasyminikit (Qiagen, Hilden,
Germany) and stored at 20°C until further use. RNA extraction was
carried out according to the instructions provided by the manufacturers.
Synthesis of cDNA for quantitative reverse transcriptase PCR (RT-PCR)
was performed with 2 g of RNA using the Qiagen Omniscript kit with
random primers according to the manufacturer’s instructions. Quantita-
tive PCRwas performed with 10l of cDNA (diluted 1:50 in water) using
the QuantiTect SYBR green PCR kit (Qiagen) in 20 l standard reaction
mixtures containing 0.5Mforward and reverse primers (MWGBiotech,
Ebersberg, Germany) as listed in Table 1. Furthermore, control PCRswith
RNA equivalents from samples that had not been reverse transcribed into
cDNA (data not shown) confirmed that no DNA was amplified from any
residual genomic DNA that might have resisted DNase I digestion (see
above). PCR was started by initiating the hot-start Taq DNA-polymerase
reaction at 95°C (10min). Subsequent DNA amplificationwas performed
in 40 cycles, including denaturation (94°C for 15 s), annealing (58°C for
15 s), and extension (72°C for 30 s); temperature transition rates in all
cycle steps were 20°C/s. Fluorescence was measured at 79°C on a Corbett
cycler (Corbett Research,Mortlake, Australia). From the quantitative RT-
Winzer et al.
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PCR,mean values (MV) (standard error [SE]) from four replicates were
assessed, and expression levels were given as values in arbitrary units rel-
ative to the amount of Gra rRNA.
Immunofluorescence staining. HFF monolayers grown in 24-well
plates on poly-L-lysine coated coverslips were infected with 2  104 N.
caninumNc-Liv or T. gondiiME49 tachyzoites. After initial growth for 24
h, specimens were exposed to 2.5 M BKI-1294 at periods of 2, 4, or 6
days. They were then washed once in PBS and fixed and processed for
immunofluorescence as previously described (18). The following anti-
bodies (Abs) were used: (i) a whole N. caninum extract rabbit antiserum
(16), diluted 1:2,500; (ii) mAbCC2, a rat monoclonal Ab reacting with a
yet uncharacterized cyst wall antigen (20), diluted 1:300; (iii) -BAG1, a
polyclonal rabbit Ab directed against BAG1, a classical bradyzoite-specific
antigen (21–23), diluted 1:300; (iv) -SAG1, a mouse monoclonal Ab
directed against the major immunodominant tachyzoite surface antigen
(24), diluted 1:300; and (v) a whole T. gondii extract rabbit antiserum,
diluted 1:2,000. Primary antibodies were applied for 45min at room tem-
perature in PBS with 0.3% bovine serum albumin (BSA). After three
washes in PBS for 5 min each, the corresponding secondary antibody
conjugates (anti-mouse fluorescein isothiocyanate [FITC] or anti-rabbit
Texas Red [Sigma-Aldrich]) were applied at a dilution of 1:300 in PBS
with 0.3% BSA. After three washes in PBS for 5 min each, specimens were
incubated in 4=,6-diamidino-2-phenylindole (diluted 1:300 in PBS) and
then embedded in Vectashield mounting medium (Vector Laboratories,
Burlingame, CA, USA). All specimens were viewed on a Nikon Eclipse
E800 digital confocal fluorescence microscope. Processing of images was
performed using the Openlab 5.5.2 software (Improvision, PerkinElmer,
Waltham MA, USA).
Animal experimentation. All protocols involving animals were ap-
proved by the Animal Welfare Committee of the Canton of Bern under
the license BE115/14. All animals used in this study were handled in strict
accordance with practices made to minimize suffering.
Assessment of potential effects of the BKI-1294 on pregnancy out-
come in noninfectedBALB/cmice.Animal procedureswere approved by
the Animal Welfare Committee of the Canton of Bern (approval no.
BE115/14). Forty female and 20 male BALB/c mice, 8 weeks of age, were
purchased from a commercial breeder (Charles River, Sulzberg, Ger-
many) and were maintained in a common room under controlled tem-
perature and a 14-h dark and 10-h light cycle according to the guidelines
set up by the animal welfare legislation of the Swiss Veterinary Office
(approval no. BE 105/14). Female mice were oestrus-synchronized by the
Whitten effect and were mated for three nights by housing 1 male with 2
females (25). At day 9 of pregnancy, the pregnant females were randomly
distributed into 2 experimental groups of 10 females each. One group was
treated with the BKI-1294 (50mg/kg of body weight per day emulsified in
100 l 0.5% CMC in water) for a period of 8 days by gavage once a day,
and the other group was treated identically with CMC but without drug.
Micewere separated into individual cages at day 18 of pregnancy, and they
gave birth on days 20 to 22. Dams and offspring were maintained for at
least 1 month after birth and were closely monitored to rule out any
adverse effects due to drug treatment.
Assessment of the efficacy of treatment with the BKI-1294 in mice
infected with the N. caninum Nc-Liv isolate. Thirty female and 15 male
BALB/c mice, 8 weeks of age, were maintained as described above. Preg-
nancywas achieved after synchronization of oestrus followedbymating (1
male housed with 2 females) for 3 nights. They were all infected by intra-
peritoneal (i.p.) inoculation of 2 106N. caninumNc-Liv tachyzoites on
day 7 postmating. Following infection and for the duration of the entire
experiment,micewere inspected twice daily for clinical signs (ruffled coat,
apathy, and hind limbparalysis) andwere categorized according to a score
sheet approved by the local authorities. Two days after infection, 12 preg-
nant and 12 nonpregnant mice were randomly allocated into experimen-
tal groups of 6 (2 pregnant and 2 nonpregnant groups). One pregnant and
one nonpregnant group were given the BKI-1294 (50 mg/kg/day emulsi-
fied in 100 l 0.5% CMC in water) for a period of 8 days by oral gavage
once a day, while the other two control groups received CMC in water.
Pregnant mice were placed into individual cages on day 18 of pregnancy,
and they all gave birth on days 20 to 22. Dams were euthanized in a CO2
chamber and offspring decapitated immediately after birth. The nonpreg-
nant mice were euthanized in a CO2 chamber at 15 days p.i. Brains and
sera were sampled and stored at20°C for subsequent analyses.
Assessment of the efficacy of treatment with the BKI-1294 in non-
pregnant and pregnant BALB/c mice experimentally infected with the
N. caninum Nc-Spain7 isolate. Sixty female and 30 male BALB/c mice
were housed, and pregnancy was achieved after synchronization of oes-
trus as described above. Subsequently, female mice were randomly dis-
tributed in 3 groups of 16 mice each. Mice from groups 1 and 2 were
subcutaneously challenged with 105 tachyzoites of the Nc-Spain7 isolate
at midgestation (days 7 after mating), while mice from group 3 were left
unchallenged and received a culture medium inoculation (26). Two days
after infection, all mice from group 1 were given the BKI-1294 (50mg/kg/
day emulsified in 100 l corn oil) for a period of 6 days by gavage once a
day, while the group 2 mice received corn oil alone. Prior to gavage, the
corn oil-drug mixture was heated to 37°C to enhance solubility of the
drug. Group 3 remained untouched. Pregnancy was confirmed between
days 15 and 18 of gestation, and pregnant mice were then allocated into
single cages to give birth on days 20 to 22 and to rear their pups for an
additional 30 days. During this time, nonpregnant mice were maintained
in cages of 3 to 5. Nonpregnant mice, dams, and their offspring were
evaluated for clinical signs of disease twice a day from the day of birth to
day 30 postpartum (p.p.) according to the scoring scheme as above. Data
on the number of female mice that became pregnant, litter size (number
of delivered pups per dam), early pup mortality (number of full-term
dead pups from birth until day 2 p.p.), postnatal mortality (number of
TABLE 1 Overview of primers used in this study
Primer Gene product (accession no.a) Sequence
NcSAG1-F N. caninum SAG1 (FR823385; region 1666638–1673366) GGGTCGTAGGCTTGATGG
NcSAG1-R GCAGCAGCGGCAAGGGG
TgSAG1-F T. gondii SAG1 (TGME49_264660) CTTCAGGACGTCGTTCCC
TgSAG1-R CACCTTTGCAGGCTTGCC
NcBAG1_F N. caninum BAG1 (NCLIV_chrVIIb; region 2868187–2869925) CTCGACTTCATGGATGAGG
NcBAG1_R CTTCTATGGTAACGTCATCC
TgBAG1-F T. gondii BAG1 (TGME49_259020) CTAGACTATTTGGAT
TgBAG1-R CTGTCGAACTCCACG
NcGra2_F N. caninum GRA2 (AF196293.1) GCCATGCGTGTATCGCCC
NcGra2_R TTCGCAGTAAACTGCTTGAG
TgGra2_F T. gondii GRA2 (TGME49_227620) CCAGAAGAACCGGTTTCCC
TgGra2_R AACGGTCACCATGCCCCT
a The accession numbers for T. gondii SAG1, BAG1, and GRA2 are from ToxoDB (http://www.toxodb.org), and the accession number for N. caninum BAG1 is from GeneDB
(http://www.genedb.org).
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dead pups from day 3 to 30 p.p.), and clinical signs in dams and nonpreg-
nant mice were recorded. Dams were weighed at days 15 and 30 p.p., and
neonates were weighed every second day from day 15 p.p. onwards until
the end of the experiment (day 30 p.p.). Nonpregnant mice were weighed
once a week. Surviving dams, nonpregnant mice, and pups were eutha-
nized in a CO2 chamber latest at 30 days p.p. (approximately day 44 p.i.).
Blood from dams and nonpregnant mice was recovered by cardiac punc-
ture, and serum samples were obtained to assess humoral immune re-
sponses.
Analysis of biological samples from in vivo experiments. To quan-
tify the parasite load in brains, DNA purification was performed employ-
ing the DNeasy blood and tissue kit (Qiagen, Basel, Switzerland) accord-
ing to the standard protocol suitable for animal tissues. The DNA
concentrations in all samples were determined using the QuantiFluor
dsDNA system (Promega,Madison,WI, USA) according to themanufac-
turer’s instructions and adjusted to 5 ng/l with sterile DNase-free water.
Quantification of parasite loads in the brains of nonpregnant mice and
dams was done as described previously (10, 27). Seropositivity for N.
caninum was assessed as described previously (28, 29).
Statistics. Fifty percent inhibitory concentrations (IC50s)were calculated
after the logit log-transformation of the relative growth (RG; control  1)
according to the formula ln(RG/[1RG]) a ln(drug concentration)
b and subsequent regression analysis by the corresponding software tool
contained in the Excel software package (Microsoft, Seattle, WA, USA).
Statistical analysis of the parasite burdens in brains was done using the
Kruskal-Wallis test. Comparison of positive and negative animals was
performed using the chi-square test. All analyses were performed using
the software package R (30).
RESULTS
N. caninum andT. gondii infections display similar sensitivities
to treatment with BKI-1294 in vitro.Different concentrations of
BKI-1294 were added to in vitro cultures of N. caninum Nc-Liv
and Nc-Spain7, two wild-type T. gondii strains (RH and ME49),
and the two transgenic T. gondii strains (CDPK1_wt and
CDPK1_G128M). The drug was added to HFF monolayers just
prior to inoculation of tachyzoites. This resulted in IC50s ranging
from 20 nM (T. gondii RH) up to 360 nM (N. caninum Nc-Liv)
(Table 2). The T. gondii strain CDPK1_G128M overexpressing a
plasmid-encoded CDPK1 enzyme with a mutated (G to M) gate-
keeper residue at position 128 was much less susceptible com-
pared to the T. gondii RH andME49 wild-type strains. The corre-
sponding transgenicwild-type cell line, expressing an ectopic copy
of nonmutated CDPK1, also exhibited a slightly higher IC50 than
the wild-type strains in accordance to previous findings (12).
Treatments of N. caninum and T. gondii infections with
BKI-1294 interferes with the separation of daughter zoites and
leads to the formation of multinucleated complexes. The effects
of continued BKI-1294 treatments in already infectedHFFmono-
layers were visualized under a light microscope and by TEM. T.
gondii ME49 and RH tachyzoites were allowed to invade HFF
monolayers for 2 h prior to addition of 2.5 M BKI-1294 or the
corresponding amount of DMSO. Inspection by light microscopy
showed that in treated and untreated cultures, large parasito-
phorous vacuoles were formed, indicating that parasite replica-
tion took place. However, the interior of the vacuoles in BKI-
1294-treated cultures exhibited clear alterations compared to
parasitophorous vacuoles from cultures maintained in the ab-
sence of the drug (see Fig. 1A through D). In untreated HFF, large
vacuoles containing numerous tachyzoites were present after 2 to
3 days (Fig. 1A and C) followed by egress of tachyzoites from day
3 onwards. In BKI-1294-treated cultures, parasitophorous vacu-
oles had also increased in size, but egress of tachyzoites was
blocked, and the interior of the vacuoles was not filled with indi-
vidual parasites but larger structures of unknown nature (Fig. 1B
andD). Similar findingswere obtained in cultures infectedwithN.
caninumNc-Liv andNc-Spain7 (data not shown). These observa-
tions were in line with earlier findings on transgenic Nc-betaGal
treated with BKI-1294. Thus, TEMwas used for further visualiza-
tion of these interior complexes.
Figures 1E and F show nontreated T. gondii ME49 and RH
tachyzoites cultured in HFF in the absence of drug at day 3 p.i.
Tachyzoites proliferate intracellularly within a parasitophorous
vacuole, surrounded by a parasitophorous vacuole membrane,
and mostly individual tachyzoites are seen. Upon treatment with
BKI-1294, the first signs of an inhibition of separation of newly
formed tachyzoites in the two T. gondii strains were already ob-
served on day 2 of treatment, as seen forT. gondiiME49 in Fig. 1G,
and complexes increased in size and number of nuclei on day 4
(Fig. 1H). Figure 1I shows a vacuole containing two complexes of
T. gondii ME49 treated with BKI-1294 for 6 days, with the two
complexes embedded in a granular vacuolar matrix. One of these
complexes already exhibited clear signs of structural impairment
such as extensive intracellular vacuolization, while the other one
still had more intact features, with a higher number of detectable
nuclei and morphologically intact mitochondria and apical
conoids being formed and protruding from its body. Figure 1J
shows a multinucleated complex formed by N. caninum Nc-Liv
tachyzoites treatedwith BKI-1294 for 6 days. Similar features were
observed when T. gondii RH tachyzoites were treated with BKI-
1294 for 6 days (Fig. 2A andB). In contrast, BKI-1294 treatment of
the T. gondii cell line CDPK1_G128M overexpressing a mutated
gatekeeper residue with a transition from G to M at position 128
did not lead to themultinucleated complex phenotype as observed
for the other cell lines (Fig. 2D). These tachyzoites underwent
proliferation within a parasitophorous vacuole and separated in a
normal manner, in contrast to their respective wild type, T. gondii
CDPK_wt overexpressing the wild-type CDPK1 (Fig. 2C). How-
ever,T. gondiiCDPK1_G128M exhibited a slightly altered pheno-
type with increased intracytoplasmic vacuole formation (Fig. 2D).
BKI-1294 treatment results in deregulated antigen expres-
sion inN. caninum andT. gondii. In order to investigate whether
bradyzoite-specific gene expression was induced by BKI-1294,
HFF monolayers were infected with Nc-Liv or T. gondii ME49,
cultured for 2 days and treated with BKI-1294 or with DMSO as a
solvent control. During the next 4 days, the infected cell layers
were harvested, and mRNA levels of the bradyzoite-specific anti-
gen BAG1 and the tachyzoite-specific antigen SAG1 were deter-
mined in relation to Gra2 mRNA, which is expressed in brady-
zoites and tachyzoites. After 2 and 4 days, BAG1 levels were
TABLE 2 IC50 of BKI-1294 in N. caninum and T. gondii strains
a
Strain IC50 (nM)
N. caninum Nc-Liv 360 50
N. caninum Nc-Spain7 270 20
T. gondii RH 20 10
T. gondii ME49 220 60
T. gondii RH CDPK1-wt 480 100
T. gondii RH CDPK1-G128 M 2,260 400
a HFF monolayers were treated with different concentrations of BKI-1294 or DMSO as
a solvent control, infected with 5 104 tachyzoites, and incubated for 3 days. Cells
were harvested, parasite load was determined, and IC50s were calculated as described.
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FIG 1 Effects of BKI-1294 treatment on intracellular T. gondii andN. caninum tachyzoites. (A to D) Phase contrast images of T. gondiiME49 (A, B) and RH (C,
D) cultured inHFF in the absence (A, C) or presence (B,D) of BKI-1294. Arrows point toward parasitophorous vacuoles. (E, F) Electronmicrographs ofT. gondii
ME49 and RH tachyzoites, respectively, cultured in HFF in the absence of the drug for 3 days. Tachyzoites exhibit mostly single nuclei (N), and rhoptries (rho),
dense granules (dg), and mitochondria (mi) are visible. The interior of the parasitophorous vacuole is filled with a parasitophorous vacuole tubular network
(PVN). (G, H, and I) Transition of T. gondii ME49 tachyzoites into multinucleated complexes upon exposure to BKI-1294 for 2 (G), 4 (H), and 6 (I) days.
Emerging apical complexes are marked with an asterisk (*), and multiple nuclei are visible (N), as well as rhoptries (rho) and dense granules (dg). Note that at
6 days of BKI-1294 treatment, the matrix of the parasitophorous vacuole becomes more granular (PVMa). (J) IntracellularN. caninumNc-Liv complex formed
after 6 days of BKI-1294 treatment. (E) Bar 1 m; (F) bar 0.8 m; (G) bar 1.2 m; (H) bar 1.8 m; (I) bar 2.5 m; (J) bar 2.1 m.
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FIG 2 Complex formation of wild-type T. gondii RH and CDPK1_wt but not T. gondii CDPK1_G128M upon exposure to BKI-1294. (A) Low-magnification
view of a large multinucleated complex formed by T. gondii RH; (B) the boxed area is shown enlarged. (C) T. gondii CDPK1_wt treated with BKI-1294. (D) No
complexes are formed uponBKI-1294 treatment ofT. gondiiCDPK1_G128M.N, nucleus;mi,mitochondria; rho, rhoptry; dg, dense granules. (A) Bar 2.5m;
(B) bar 0.6 m; (C) bar 2 m; (D) bar 1 m.
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strongly increased in cells infected with N. caninum Nc-Liv or
T. gondiiME49 treatedwith BKI-1294. SAG1 levels remained con-
stant in Nc-Liv and were even increased in T. gondii ME49 upon
BKI-1294 treatment (Table 3). Conversely, BAG1 expression was
reduced in T. gondii CDPK1_G128M compared to its isogenic
strain overexpressing wild-type CDPK1 (Fig. 3).
Moreover, the expression of tachyzoite-specific antigen SAG1
and the bradyzoite marker BAG1 in BKI-1294-treated and un-
treatedT. gondiiME49 andN. caninumNc-Livwas investigated by
immunofluorescence (Fig. 4 and 5). In addition, a second brady-
zoitemarker recognized by themAbCC2 (18, 31)was also studied.
Toxoplasma (Fig. 4A through D and M through P) and Neospora
(Fig. 5A throughD andM through P) control culturesmaintained
in the absence of the drug are shown at 3 days postinfection, as
they were normally lysed completely after 4 to 5 days. In these
controls, SAG1 expression was always evident on tachyzoites lo-
calized in large parasitophorous vacuoles, while staining with an-
tibodies against BAG1 and the mAbCC2 were either sparse or
nonexistent, indicating that in nontreated cultures the protein
expression levels of these antigens were low. In contrast, BKI-1294
treatment led to increased BAG1protein expression andmAbCC2
labeling in T. gondii (Fig. 4E through L and Q through T) and N.
caninum (Fig. 5E through L and Q through T). Most notably,
BAG1 (Fig. 4A through L and Fig. 5A through L) was detected
already after 4 days of BKI-1294 treatment, and staining intensity
increased consistently with time. Within these multinucleated
complexes, SAG1 and BAG1 were distributed unevenly, and in
many instances, staining of BAG1 antigen occurred in regions
with lower SAG1 expression. MAbCC2 labeling was compara-
tively assessed to staining of complexes with a polyclonal antise-
rum raised against crude T. gondii (Fig. 4M through T) and N.
caninum antigens (Fig. 5M through T), and staining intensity also
increased with time.
Treatment of pregnant mice with BKI-1294 has no side ef-
fects and protects pups from vertical transmission of N. cani-
num. In order to investigate whether BKI-1294 affected preg-
nancy and the number of offspring, pregnant mice were treated
with BKI-1294 (50 mg/kg/day) during 8 days or with the vehicle
(CMC, 0.5%) alone. The numbers of offspring in the different
treatment groups were virtually identical. Fifty-four offspring
were born in the BKI-1294 treatment group, and 46 pups were
born in the control group (with 2 stillborn pups in each group).
No negative impact on the further development of offspring mice
was detected during at least 1 month after birth (data not shown).
Thus, BKI-1294 treatment did not affect pregnancy outcome.
These findings prompted us to proceed to experimental treat-
ments of infected mice with BKI-1294. In a first experiment, non-
pregnant mice and pregnant mice were infected at the same time (7
days postmating) by intraperitoneal injection of 2 106N. caninum
Nc-Liv tachyzoites. Twodays later, BKI-1294 treatmentwas initiated
by oral gavage (50 mg/kg/day for 8 days) formulated in 0.5% CMC,
while the control groups received CMC only. None of the mice died
during the 2-week period following infection, but 4 out of 6 dams in
the control group exhibitedmild symptoms such as ruffled coat and
moderate weight loss, while in all other groups, no clinical signs were
detected. After the dams gave birth, allmice including offspringwere
euthanized, and the effects of the treatment were evaluated. Thirty-
nine pups were born in the control group, and 27 pups were born in
the BKI-1294-treated group (the difference was not statistically sig-
FIG 3 Quantification of BAG1 and SAG1 gene expression during treatment
with BKI-1294. Confluent HFF monolayers grown in 6-well plates were in-
fected with 2.5  104 tachyzoites of T. gondii RH overexpressing
CDPK1_G128M or wild-type CDPK1. Treatments with 5 M BKI-1294 or
DMSO (control) were initiated 2 days postinfection. After different time
points, the adherent cells were harvested for RNA extraction. mRNA levels of
BAG1, SAG1, and GRA2 were quantified by real-time RT-PCR. Mean values
(SE) from four replicates were assessed, and expression levels of BAG1 (bra-
dyzoite specific) or SAG1 (tachyzoite specific) relative to the amount of GRA2
(overall) mRNA were given as multiples of the corresponding DMSO control
values (MV SE for quadruplicates).
TABLE 3 BAG1 and SAG1 gene expression during treatment with BKI-
1294a
Transcript
Relative mRNA level
N. caninum Liverpool T. gondii ME49
BAG1
Day 2 13 4 729 220
Day 4 7 1 413 77
SAG1
Day 2 1.4 0.4 17 1
Day 4 1.3 0.2 31 2
a Confluent HFF monolayers grown in 6-well plates were infected with 2.5 104 Nc-
Liv or TgME49 tachyzoites. Treatment with 5 M BKI-1294 or DMSO (control) was
initiated 2 days postinfection. After different time points, the adherent cells were
harvested for RNA extraction. mRNA levels of BAG1, SAG1, and Gra2 were quantified
by real-time RT-PCR. Mean values (SE) from four replicates were assessed, and
expression levels of BAG1 (bradyzoite specific) or SAG1 (tachyzoite specific) relative to
the amount of GRA2 (overall) mRNA were given as multiples of the corresponding
DMSO control values (MV SE for quadruplicates).
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nificant). All infected mice were seropositive for N. caninum. All
control mice (nonpregnant and dams) were tested PCR-positive in
the brain, whereas only one nonpregnant female and one dam were
positive in the BKI-1294-treated groups. Of the 27 pups born in the
BKI-1294-treated group, all brains were real-time PCR-negative,
while in the 39 pups born in the control group, 21 tested positive.
These differences were highly significant (Table 4).
In order to assess the reproducibility of these findings using an-
other virulent N. caninum isolate, another mode of infection, and
another formulationof thecompound, a secondexperimentwasper-
formedaccording to the recently standardized infectionmodel estab-
lishedbyArranz-Solís et al. (26).Miceweremated as described above
and infected 7 days postmating by subcutaneous injection of 105 N.
caninumNc-Spain7 tachyzoites. Twodays later, BKI-1294 treatment
was initiated by oral gavage (50mg/kg/day formulated in corn oil for
a period of 6 days). Pregnant and nonpregnant mice were separated
and analyzed separately as described. All infectedmice were seropos-
itive forN. caninum. None of the nonpregnant mice exhibited clin-
ical signs of neosporosis during the 3weeks following infection. After
the dams gave birth, offspring and damsweremaintained for 30 days
in order to investigate how the treatments had an impact in the long
termduring the postnatal phase in dams and offspring.Whereas 5 of
FIG 4 BKI-1294 treatment of T. gondii ME49 cultured in HFF induces BAG1 protein expression and increased staining with mAbCC2. Controls (A to D and
M to P) were fixed and processed after 3 days, and BAG1 labeling is shown after 4 and 6 days of BKI-1294 treatment. Staining with mAbCC2 is shown after
6 days of treatment (E to L and Q to T). Note the increased staining of the two bradyzoite markers in BKI-treated cells.
Winzer et al.
6368 aac.asm.org October 2015 Volume 59 Number 10Antimicrobial Agents and Chemotherapy
 o
n
 Septem
ber 19, 2015 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
8 dams of the placebo control group showed clinical signs and one
died before the end of the experiment, only 2 of 10 mice from the
treated group showed mild clinical signs and none of them died be-
fore the end of the experiment (Table 5). Cerebral parasite loads in
nonpregnantmice and dams as quantified by PCRwere significantly
lower in the treated group, demonstrating that BKI-1294 treatment
has essentially prevented cerebral infection with N. caninum Nc-
Spain7 (Fig. 6A).
After 30 days p.p., all surviving mice including offspring were
euthanized, and the effects of BKI-1294 exposure were evaluated
with regard to cerebral infection in surviving dams and nonpreg-
nant mice and pups. The number of pups per dam was not signif-
icantly affected by the treatment. In the two groups, two pups died
immediately after birth. Later, 40 of the remaining 41 pups died in
the control group but only 4 of 56 in the treated group (see Fig.
6B). Based on previous results (26), the dead pups were consid-
ered PCR-positive for N. caninum. After 30 days, all survivors
were tested by PCR for the presence ofN. caninum in their brains.
The last survivor from the control groupwas brain positive, aswell
as 5 of 52 surviving pups from the treated dams. Thus, mortality
and transmission of N. caninum to pups was strongly reduced by
BKI-1294 treatment of the dams (Fig. 7). The differences were
highly significant (Table 5).
DISCUSSION
In apicomplexan parasites, calcium-mediated signaling plays a
major role in a variety of crucial activities, including events that
ensure progression in the life cycle such as secretion, gliding mo-
FIG 5 BKI-1294 treatment ofN. caninumNc-Liv cultured inHFF induces BAG1 protein expression and increased staining withmAbCC2. Controls (A toD and
M to P) were fixed and processed after 3 days, and BAG1 labeling is shown after 4 and 6 days of BKI-1294 treatment. Staining withmAbCC2 is shown after 6 days
of treatment. Note the increased staining of the two bradyzoite markers.
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tility, and entry into host cells (32), as well as intracellular prolif-
eration, cytokinesis, and stage differentiation (33). Calcium also
activates CDPKs, which are found in plants, ciliates, and in api-
complexan parasites but not in mammalian cells (34). They are
thus promising targets for chemotherapeutical intervention. In T.
gondii, it was shown that CDPK1, a member of the serine/threo-
nine kinase family, regulates the calcium-dependent pathway of
microneme secretion and governs cell attachment (35), migra-
tion, and microneme secretion (36). The ATP-binding site of T.
gondiiCDPK1, but also of other related apicomplexans, such asN.
caninum and Cryptosporidium parvum, is characterized by a small
glycine gatekeeper residue (10, 37), while most mammalian ki-
nases have larger residues such as methionine or phenylalanine at
that position. Selective and potent inhibitors have been generated
that take advantage of the enlarged space in the CDPK1 ATP-
binding site (37–39). Benzoyl benzimidazole-based selective in-
hibitors and BKIs based on a pyrazolopyrimidine scaffold can
block T. gondii CDPK1 and affect host cell invasion (40–42).
Here, we focus on the pyrazolopyrimidine compound BKI-
1294. BKI-1294was reported earlier to inhibit host cell invasion of
transgenic T. gondii RH and N. caninum tachyzoites expressing
beta-galactosidase, with IC50s of 137 and 32 nM, respectively, if
the compound was added to the cultures at the time point the
parasites were allowed to invade their host cell (10, 39). We show
here that BKI-1294 also exhibited in vitro activity against the vir-
ulentN. caninum isolates Nc-Liv andNc-Spain7 (IC50s 360 and
270 nM, respectively) and similarly against the cyst-forming T.
gondii ME49 strain, while T. gondii RH tachyzoites were much
more susceptible (IC50  20 nM). The value we obtained for T.
gondii RH inhibition (20 nM) differs substantially from those re-
ported previously (39). However, it is important to note that in
this study parasite loads were quantified by real-time PCRwhile in
earlier reports transgenic parasites expressing beta-galactosidase
were used, and some degree of variation may be attributed to
different culture conditions, host cells, and slight variations in
protocols for parasite isolation prior to infection of HFF. In addi-
tion, strains and isolates that have been maintained in culture for
extended periods of timemay exhibit various drug susceptibilities.
However, in accordance with an earlier report (12), the sensitivity
to BKI-1294 was entirely lost in T. gondii CDPK1_G128M, which
overexpresses a mutated TgCDPK1. Crystallographic confirma-
tion of the interaction between BKI-1294 and NcCDPK1 showed
TABLE 5 Effects of BKI-1294 treatments on clinical signs, mortality,
fertility, and cerebral N. caninum Nc-Spain7 infection in nonpregnant
mice, dams, and pupsa
Parameter BKI-1294 Placebo control
Nonpregnant females (no./total no.)
Total no. 6 8
Clinical signs 0/6 0/8
Mortality 0/6 0/8
Seropositive 6/6 8/8
N. caninum positive 1/6b 8/8
Dams and pups (no./total no.)
Total no. of dams 10 8
Clinical signs 2/10c 5/8
Mortality 0/10d 1/8
Seropositive dams 10/10 8/8
N. caninum-positive dams 3/10b 8/8
Pregnancy rate 10/16 8/16
Total no. of pups 58 43
Litter size avg (no. of pups/no. of dams) 58/10d 43/8
Neonatal mortalitye 2/58d 2/43
Postnatal mortalityf 4/56g 40/41
N. caninum-positive pups 9/58g 43/43
a Mice were treated with BKI-1294 in corn oil or with corn oil alone as a placebo
control, infected with Nc-Spain7, and sacrified as described in Materials and Methods.
Adults and surviving pups were tested for the presence of N. caninum in their brains
with a specific real-time PCR. Pups that had died before the end of the experiment were
considered N. caninum positive. Respective numbers of animals in control and 1294-
treated groups were compared by chi-square tests.
b P	 0.005.
c P	 0.1.
d P
 0.1.
e Proportion of pups born dead or that died within the 2 first days postpartum.
f Proportion of pups dead from days 3 to 30 postpartum.
g P	 0.001.
FIG6 Mice treatedwith BKI-1294 have a lower cerebral parasite load. BALB/c
mice were infected with Nc-Spain7 tachyzoites and subsequently treated with
BKI-1294 in corn oil (1294) or corn oil only (control) as detailed in Materials
andMethods. Nonpregnantmice were euthanized 3 weeks p.i., and damswere
euthanized 30 days postpartum. After euthanasia, brains were collected and
the amount of tachyzoites was determined by quantitative PCR (*, P	 0.005;
**, P	 0.001; Kruskal-Wallis test).
TABLE 4 Effects of BKI-1294 treatments on cerebral N. caninum Nc-Liv
infection in nonpregnant mice, dams, and pupsa
Parameter BKI-1294 Placebo control
Nonpregnant females (no./total no.)
Total no. 6 6
Seropositive 6/6 6/6
N. caninum positive 1/6b 6/6
Dams and pups (no./total no.)
Total no. of dams 6 6
Seropositive dams 6/6 6/6
N. caninum-positive dams 1/6b 6/6
Total no. of pups 27 39
N. caninum-positive pups 0/27c 21/39
Stillborn pups 6/27d 8/39
a Mice were treated with BKI-1294 in CMC or with CMC alone as a placebo control,
infected with Nc-Liv, and sacrificed as described in Materials and Methods. Adults and
pups were tested for the presence of N. caninum in their brains with a specific real-time
PCR. Respective numbers of animals in control and 1294-treated groups were
compared by chi-square tests.
b P	 0.005.
c P	 0.001.
d P
 0.1.
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that binding was entirely consistent with that previously deter-
mined for the TgCDPK1 homologue, which is 96% identical and
differs in the active site by only one residue (10). This clearly
indicates that CDPK1 represents the main target for BKI-1294 in
T. gondii and N. caninum.
However, BKIs might also affect other targets. We have
recently shown that exposure of intracellular Nc-betaGal
tachyzoites to BKI-1294 did not only inhibit egress but led to the
formation of largemultinucleated complexes within 5 to 9 days of
culture, which can be visualized by TEM (10). Here, we demon-
strate that similar multinucleated complexes occurred upon ex-
posure of T. gondii ME49 and T. gondii RH tachyzoites if treat-
ment with BKI-1294 was initiated after host cell invasion has
already taken place. These complexes contained several nuclei and
protrusions carrying features of the apical complex such as
conoid, dense granules, rhoptries, and micronemes. Thus, DNA
replication and daughter nucleus formation took place; however,
cytokinesis of the daughter cells was not completed. Many com-
plexes were still clearly viable after 6 days of in vitro treatment,
while others showed signs of deterioration. However, BKI-1294
treatment of the resistant T. gondii cell line CDPK1_G128M did
not lead to the multinucleated complex phenotype seen in the
wild-type cell lines, suggesting that the observed effect may have
some association with CDPK1 inhibition. The various metabolic
pathways for which TgCDPK1 andNcCDPK1 are associated have
not been fully defined. We have however shown that TgCDPK1
was highly localized in the cytoplasmbut also found in the nucleus
(12). Nuclear localization suggests that the TgCDPK1 may be re-
sponsible for phosphorylating nuclear proteins, potentially relay-
ing a shift in transcription associated with invasion and/or other
yet to be defined functions associated with cytokinesis of the
daughter cells.We also show that intracellularNeospora andToxo-
plasma exposed to BKI-1294 treatment exhibited markedly ele-
vated BAG1 transcript levels and increased labeling by antibodies
directed against BAG1 and by the mAbCC2, another marker for
bradyzoite stage differentiation (18).
Abnormally enlarged parasites and upregulation of brady-
zoite-specific gene expression upon protein kinase inhibitor treat-
ments have been reported by others as well (43, 44). Moreover,
BKI analogs 1NM-PP1, 3MB-PP1, and 3BrB-PP1 increased BAG1
gene promoter activity (45). Protocols for in vitro induction of
tachyzoite-to-bradyzoite stage conversion such as high pH and
CO2 depletion also cause defects in cytokinesis and asynchronous
cell division (46). However, rather than postulating that BKI-1294
treatment causes bradyzoite stage conversion, we hypothesize that
exposure to BKI-1294 leads to deregulated gene expression, which
does not necessarily interfere in DNA replication but severely
hampers cytokinesis and thus the separation of newly formed
daughter zoites.
A secondary BKI target that is actually involved in cytoki-
nesis has been defined (47), showing that mutations in the T.
gondii mitogen-activated protein kinase-like 1 (TgMAPKL-1;
TGME49_312570) resulted in a 3.5-fold increased resistance of
these parasites against the BKI 1NM-PP1. Treatment of T. gon-
dii tachyzoites with the BKI 1NM-PP1 also led to enlarged, multi-
nucleated parasites that were severely impaired in coordinated cell
cycle progression. Furthermore, a single mutation in the gate-
keeper residue of this kinase restored the inhibitory effect of the
BKI 1NM-PP1 (13). Comparison of the genomes of N. caninum
and T. gondii reveals the presence of a TgMAPKL-1 orthologue in
N. caninum (NcMAPK-3; NCLIV_056080), with a highly con-
served kinase domain of 80% identity.However, whether the BKI-
1294 also inhibits TgMAPKL-1 and NcMAPK-3 activities is not
known to date. In the N. caninum genome, other enzymes with
small gatekeeper residues were identified that BKI-1294 may po-
tentially inhibit, includingNcCamK (NCLIV_046430) with an al-
anine gatekeeper, an NcAGC-like kinase (NCLIV_016060) with a
serine gatekeeper, and an NcROP-like kinase (NCLIV_030990)
with a threonine gatekeeper (10). Engagement ofmultiple parasite
targets may be a potential advantage, especially since BKI-1294
was shown to be parasite specific and exhibits very low toxicity in
mammalian cells and no off-target inhibition of small gatekeeper
(threonine) human protein kinases (39, 48).
To provide a proof of concept that the BKI-1294 can prevent
Neospora-related abortion in cattle, we investigated the effects of
BKI-1294 treatments in a pregnant mouse model. The first in vivo
study showed that oral application of BKI-1294 at a dosage of 50
mg/kg/day for a period of 8 days in pregnant, but noninfected,
mice had no negative impact, neither on litter size, neonatal mor-
tality, nor subsequent development of the offspring during 1
month postpartum. This is in linewith earlier studies demonstrat-
ing that mice receiving 100 mg/kg BKI-1294 twice daily for 5 days
did not show any signs of toxicity orweight loss, andno alterations
in tissue histology, metabolic enzymes, and complete blood
counts (48). Subsequently, the two in vivo studies in N. caninum
Nc-Liv- and Nc-Spain7-infectedmice showed that BKI-1294 pre-
vented vertical transmission of N. caninum from dams to pups
without impairing vitality and fertility of the dams. Due to the
close phylogenetic relationship betweenN. caninum and T. gondii
and the similarities of the effects in the two parasites exerted by
BKI-1294 treatments, the current results in the pregnant model
forNeospora infection should motivate testing the drug in a preg-
nantT. gondiimousemodel to extend these results to that parasite.
Although BKI-1294 was surprisingly efficacious, the outcome
of these experiments is not a surprise as such. The in vivo efficacy
of this compound against other apicomplexan parasites in mice
has been previously reported, such as activity against cryptospo-
ridiosis (8) and experimental toxoplasmosis inflicted by the viru-
FIG 7 Offspring from BKI-1294-treated mice exhibit a similar survival rate as
mice from uninfected and nontreated mice. Survival curves of pups during 30
days postpartum (pp) of BKI-1294-treated (1294) and placebo-treated (corn
oil only) groups, each of which was infected with Nc-Spain7 isolates of N.
caninum. A group that was not infected and remained untreated with any
compound (noninfected) exhibited 100% survival.
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lent T. gondii RH strain (49). The BKI 1NM-PP1 also inhibited T.
gondii RH strain infection in mice, although only when given in
high doses by i.p. injection prior to infection via the intraperito-
neal route (50). A similar BKI serieswas assessed in vivo against the
cyst-forming type II strain T. gondii Pru, and these compounds
prolonged survival and decreased the numbers of brain cysts at 30
days p.i. (38). However, in this study, compound administration
was started 1 day prior to infection and lasted for a period of 10
days. In contrast, in our experiments the BKI-1294 was adminis-
tered 48 h after infection, hence, when a robust infection and
dissemination of the parasite in the mice has already taken place.
This clearly indicates that BKI-1294 probably exerts effects in vivo
that go far beyond its expected impact on host cell invasion as the
primary target, and this may be well in line with our in vitro ob-
servations. Thus, those effects seen in vitromay also affect parasite
viability in vivo since BKI-1294 achieved therapeutic concentra-
tions in mice that mimic those of our in vitro treatment experi-
ments; the mean serum concentration after administration of 40
mg/kg of body weight for 6 consecutive days in mice resulted in a
serum concentration of 6.3  1.8 M, and the therapeutic con-
centrations in the brain are about 30%of the serum concentration
(49). Pharmacokinetic studies showed that hepatic metabolism of
BKI-1294 becomes saturated with repeated administration and
increased dosage (48). The fact that these therapeutic concentra-
tions in vivo are sufficiently high to potentially induce the forma-
tion of rather long-lived multinucleated complexes in an infected
animal may have important implications for the formation of a
sustainable immunological response. For instance, the Nc-
Spain7-infected dams were maintained for a period of 38 days
following BKI-1294 treatment, and still only minimal cerebral
parasite loads were noted. Such an immune response, directed
against antigens expressed by parasites blocked in the process of
cytokinesis but still viable,may be effective for extended periods of
time after the end of dosing, andmay well contribute to the excel-
lent efficacy of BKI-1294. This hypothesis of an enhanced antigen
expression causing a strong immune response during BKI-1294
therapy and leading to better outcomes in immunocompetent an-
imals will be the subject of future studies.
In conclusion, the broad-spectrum anti-apicomplexan com-
pound BKI-1294 exhibits excellent potency and specificity and
does not cause toxicity in pregnant mice. Its impact on CDPK1
and host cell invasion is undisputed, but potentially other targets
related to the completion of cytokinesis may also be affected. In-
tracellular parasites exposed to BKI-1294 exhibit a deregulated
gene expression and build up multinucleated and rather long-
lived complexes. Further investigations will focus on the expres-
sion profile of these complexes and their role in the immune re-
sponse in BKI-1294-treated animals.
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